🟢 Ironwood Pharmaceuticals is trading 10.61% up after raising 2026 revenue outlook

Ironwood Pharmaceuticals is trading 10.61% up at $4.17 after its November 5, 2026, third-quarter results and higher full-year outlook.

• Q3 revenue was $133.0 million, with diluted EPS of $0.36.
• 2026 revenue guidance rose to $485–$510 million from $460–$485 million.
• LINZESS U.S. sales reached $324.9 million; Ironwood also raised its LINZESS sales and adjusted EBITDA outlook.